)
Amicus Therapeutics (FOLD) investor relations material
Amicus Therapeutics Proxy Filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Special meeting scheduled for March 3, 2026, to vote on the proposed merger with BioMarin, where Amicus would become a wholly owned subsidiary of BioMarin via a merger with Lynx Merger Sub 1, Inc.
The merger agreement was signed on December 19, 2025, and the proxy materials were supplemented to address recent legal and shareholder developments.
Forward-looking statements highlight risks related to shareholder approval, regulatory conditions, competing offers, and integration challenges.
Voting matters and shareholder proposals
Stockholders are asked to vote on the adoption of the merger agreement and related transactions.
Shareholders who have not yet submitted proxies are urged to do so; those who have may change or revoke their proxies if desired.
Board of directors and corporate governance
A Transactions Committee, including the Board Chair and Audit and Compliance Committee members, was formed in March 2024 to oversee potential business development, including the BioMarin transaction.
No additional compensation was provided to committee members for their service related to the merger.
- 2025 revenue up 17% at CER to $634M; BioMarin acquisition expected Q2 2026.FOLD
Q4 202520 Feb 2026 - Shareholders to vote on a cash merger with BioMarin at a 33% premium, board recommends approval.FOLD
Proxy Filing2 Feb 2026 - Q2 revenue up 34%, non-GAAP profitability achieved, guidance raised, and $260M cash reserves.FOLD
Q2 20242 Feb 2026 - Commercial momentum and strategic investments position both products for $1B+ peak sales.FOLD
Goldman Sachs 45th Annual Global Healthcare Conference1 Feb 2026 - Shareholders to vote on BioMarin acquisition amid strong 2025 financial estimates and outlined risks.FOLD
Proxy Filing26 Jan 2026 - Strong rare disease growth, market expansion, and operational progress support profitability.FOLD
Morgan Stanley 22nd Annual Global Healthcare Conference22 Jan 2026 - Shareholders to vote on $14.50/share cash merger, with board unanimous support and full financing.FOLD
Proxy Filing21 Jan 2026 - Durable growth, expanding diagnosis, and strategic execution drive strong outlook and upside.FOLD
2024 Cantor Fitzgerald Global Healthcare Conference20 Jan 2026 - Q3 2024 revenue up 37% year-over-year, guidance raised, and non-GAAP profitability achieved.FOLD
Q3 202416 Jan 2026
Next Amicus Therapeutics earnings date
Next Amicus Therapeutics earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Explore our global coverage
)
)